【摘要】：目的探討中國(guó)1996—2014年肺癌經(jīng)濟(jì)負(fù)擔(dān)研究狀況,為肺癌防控措施相關(guān)評(píng)價(jià)及衛(wèi)生決策提供參考依據(jù)。方法以癌癥、經(jīng)濟(jì)負(fù)擔(dān)、費(fèi)用等為檢索詞,檢索中國(guó)知網(wǎng)、萬(wàn)方和Pub Med數(shù)據(jù)庫(kù)1996年1月1日—2014年12月31日發(fā)表的關(guān)于中國(guó)肺癌經(jīng)濟(jì)負(fù)擔(dān)的文獻(xiàn),再按非肺癌相關(guān)文獻(xiàn)等標(biāo)準(zhǔn)進(jìn)行排除,對(duì)最終納入的32篇文獻(xiàn)進(jìn)行摘錄,所有費(fèi)用數(shù)據(jù)均按照2013年我國(guó)醫(yī)療保健消費(fèi)價(jià)格指數(shù)行貼現(xiàn)處理,且以均值表示,同時(shí)計(jì)算年均增長(zhǎng)率。結(jié)果最終納入的32篇文獻(xiàn)中,基于住院患者和人群的研究分別有30和2篇;經(jīng)濟(jì)負(fù)擔(dān)類型方面,關(guān)注直接經(jīng)濟(jì)負(fù)擔(dān)、間接經(jīng)濟(jì)負(fù)擔(dān)、直接和間接經(jīng)濟(jì)負(fù)擔(dān)的文獻(xiàn)分別有26、1和5篇;本研究分析結(jié)果顯示,中國(guó)1996—2011年肺癌例均直接醫(yī)療費(fèi)用為10 415~27 595元,年均增長(zhǎng)率為2.2%(其中檢查費(fèi)、藥品費(fèi)和化驗(yàn)費(fèi)用年均增長(zhǎng)率分別為3.5%、-3.2%和2.2%);1997—2010年肺癌次均直接醫(yī)療費(fèi)用為9 463~38 209元,年均增長(zhǎng)率為-1.7%(其中檢查費(fèi)、藥品費(fèi)和化驗(yàn)費(fèi)年均增長(zhǎng)率分別為16.9%、-2.2%和17.3%);1996—2009年肺癌直接醫(yī)療日均費(fèi)用為426~1 036元,年均增長(zhǎng)率為6.3%;直接非醫(yī)療費(fèi)用和間接費(fèi)用因涵蓋項(xiàng)目及方法差異,無(wú)法得出趨勢(shì)數(shù)據(jù)。結(jié)論中國(guó)肺癌經(jīng)濟(jì)負(fù)擔(dān)研究數(shù)據(jù)的收集及分析方法不一,例均和次均費(fèi)用整體趨勢(shì)不明顯,但細(xì)化項(xiàng)目多呈增長(zhǎng)趨勢(shì)且幅度不同。
[Abstract]:Objective to study the economic burden of lung cancer in China from 1996 to 2014, and to provide reference for the evaluation and health decision of lung cancer prevention and control measures. Methods using cancer, economic burden and cost as the key words, we searched the literature on the economic burden of lung cancer published from January 1, 1996 to December 31, 2014 in China Zhiwang, Wanfang and Pub Med databases. Then excluded according to non-lung cancer related literature and other standards, the final included 32 articles were extracted. All the cost data were discounted according to the 2013 health care consumer price index in China, and expressed as the average value. At the same time, the average annual growth rate is calculated. Results of the 32 articles included, 30 and 2 were based on inpatient and population, respectively. In terms of economic burden types, direct economic burden and indirect economic burden were concerned. The results of this study show that the average direct medical cost of lung cancer cases in China from 1996 to 2011 was 10,4151,27,595 yuan, with an average annual growth rate of 2.2%. The average direct medical cost of lung cancer in 1997-2010 was 9,463,38,209 yuan, with an average annual growth rate of -1.7%. The average daily cost of direct medical treatment for lung cancer from 1996 to 2009 was 426m 1,036 yuan, with an average annual growth rate of 6.3%, and the direct non-medical cost and indirect cost could not obtain trend data because of the differences in items and methods. Conclusion the data collection and analysis methods of economic burden study on lung cancer in China are different, and the overall trend of average and sub-cost of lung cancer is not obvious, but most of the detailed items show an increasing trend and the range is different.
【作者單位】： 徐州醫(yī)科大學(xué)公共衛(wèi)生學(xué)院流行病學(xué)與衛(wèi)生統(tǒng)計(jì)教研室;徐州市疾病預(yù)防與控制中心慢性非傳染性疾病防治科;國(guó)家癌癥中心/中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院城市癌癥早診早治項(xiàng)目辦公室;國(guó)家癌癥中心/中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院胸外科;江蘇省疾病預(yù)防與控制中心慢性非傳染性疾病防治所;
【基金】：國(guó)家自然科學(xué)青年基金(81402740;81773521;81602930) 科技部重大慢性非傳染性疾病專項(xiàng)研究(2017YFC1308700;2017YFC1308705) 教育部高等學(xué)校博士學(xué)科點(diǎn)專項(xiàng)科研基金(20131106120014) 國(guó)家城市癌癥早診早治項(xiàng)目
【分類號(hào)】：R181.3;R734.2
，

本文編號(hào)：2240687